Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 183

Sort by

Sort Order Select

Journal Articles

Age‐adapted chemotherapy and MRD‐oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial

Blood blood.2025029611.

https://doi.org/10.1182/blood.2025029611

Published: 2025

Includes: Supplemental data

Journal Articles

LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL

Manon Delafoy, Mickaël Frédéric Bonnet, Etienne Lengliné, Agata Cieslak, Aurore Touzart, Estelle Balducci, Mathieu Simonin, Véronique Lheritier, Marie-Emilie Dourthe, Benoit Heid-Picard, Sylvain Latour, Hervé Dombret, Philippe Rousselot, André Baruchel, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi

Blood blood.2025030161.

https://doi.org/10.1182/blood.2025030161

Published: 2025

Includes: Supplemental data

Journal Articles

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Blood (2025) 145 (24): 2903–2913.

https://doi.org/10.1182/blood.2024027982

Published: 2025

Includes: Supplemental data

Journal Articles

Why is InO’s divine veil not protective against resistance?

Philippe Rousselot

Blood (2025) 145 (11): 1106–1107.

https://doi.org/10.1182/blood.2024027572

Published: 2025

Journal Articles

Involvement of Expert Patients in Simulation Courses to Train Residents on Communication of Bad News

Juliette Lambert, Paul Roux, Guy Bouguet, Flore Sicre de Fontbrune, Philippe Rousselot, Caroline Besson

Blood (2024) 144 (Supplement 1): 7954.

https://doi.org/10.1182/blood-2024-206857

Published: 2024

Journal Articles

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Blood (2024) 144 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2024-209998

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Journal Articles

Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

Philippe Rousselot, Jean-Christophe Ianotto, Philippe Quittet, Maya Hacini, Gabrielle Roth-Guepin, Mathieu Meunier, Frederic Maloisel, Valérie Coiteux, Gabriel Etienne

Blood (2024) 144 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2024-200145

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

The stepbrothers of ABLSON have their own sensitivity

Philippe Rousselot

Blood (2024) 143 (21): 2117–2118.

https://doi.org/10.1182/blood.2024024121

Published: 2024

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Old rivals become new friends

Philippe Rousselot

Blood (2024) 143 (5): 380–382.

https://doi.org/10.1182/blood.2023022822

Published: 2024

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Age‐adapted chemotherapy and MRD‐oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial

LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Why is InO’s divine veil not protective against resistance?

Involvement of Expert Patients in Simulation Courses to Train Residents on Communication of Bad News

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

The stepbrothers of ABLSON have their own sensitivity

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Old rivals become new friends

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only